Imunon, Inc. (NASDAQ:IMNN) Given Consensus Rating of “Hold” by Brokerages

by · The Cerbat Gem

Imunon, Inc. (NASDAQ:IMNN – Get Free Report) has received a consensus rating of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $232.50.

A number of research analysts have recently issued reports on the company. Brookline Capital Management reaffirmed a “buy” rating on shares of Imunon in a report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a report on Wednesday, October 8th.

Check Out Our Latest Stock Analysis on IMNN

Hedge Funds Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Riverview Capital Advisers LLC raised its holdings in Imunon, Inc. (NASDAQ:IMNN – Free Report) by 193.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 34,364 shares of the company’s stock after acquiring an additional 22,649 shares during the period. Riverview Capital Advisers LLC owned approximately 1.41% of Imunon worth $176,000 at the end of the most recent quarter. Institutional investors own 4.47% of the company’s stock.

Imunon Price Performance

NASDAQ:IMNN traded down $0.03 during trading hours on Wednesday, hitting $3.92. The stock had a trading volume of 37,030 shares, compared to its average volume of 65,433. Imunon has a one year low of $2.99 and a one year high of $41.22. The firm has a market capitalization of $12.03 million, a price-to-earnings ratio of -0.41 and a beta of 1.94. The company has a 50 day simple moving average of $3.91 and a two-hundred day simple moving average of $5.97.

Imunon (NASDAQ:IMNN – Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.57. Equities research analysts anticipate that Imunon will post -1.68 earnings per share for the current year.

Imunon Company Profile

(Get Free Report)

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.

See Also